{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=42", "query": { "intervention": "Formulation #2", "page": 42 }, "page_size": 10 }, "pagination": { "page": 42, "page_size": 10, "total_count": 1745, "total_pages": 175, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=43&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=41&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T15:17:48.430Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05584683", "title": "A Pharmacokinetic Study of LP-001 in Children With a Bacterial Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric", "Bacterial Infections" ], "interventions": [ { "name": "Amoxicillin potassium clavulanate", "type": "DRUG" }, { "name": "Amoxicillin potassium clavulanate (Augmentin ES-600)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kaizen Bioscience Co.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "24 Months", "sex": "ALL", "summary": "3 Months to 24 Months" }, "enrollment_count": 39, "start_date": "2023-08-09", "completion_date": "2024-12-16", "has_results": false, "last_update_posted_date": "2025-02-05", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05584683" }, { "nct_id": "NCT01922050", "title": "A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Actinic Keratosis" ], "interventions": [ { "name": "LEO 43204 Formulation 1", "type": "DRUG" }, { "name": "LEO 43204 Formulation 2", "type": "DRUG" }, { "name": "LEO 43204 Formulation 1 Dose X", "type": "DRUG" }, { "name": "LEO 43204 Formulation 1 Dose Y", "type": "DRUG" }, { "name": "LEO 43204 Formulation 2 Dose XX", "type": "DRUG" }, { "name": "LEO 43204 Formulation 2 Dose YY", "type": "DRUG" }, { "name": "Placebo Formulation 1", "type": "DRUG" }, { "name": "Placebo Formulation 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LEO Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2013-10", "completion_date": "2014-11", "has_results": true, "last_update_posted_date": "2025-03-06", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Lomita, California • San Diego, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lomita", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01922050" }, { "nct_id": "NCT04311710", "title": "A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumor" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "ENHANZE (rHuPH20)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2020-06-25", "completion_date": "2023-01-18", "has_results": false, "last_update_posted_date": "2023-02-24", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 2, "location_summary": "Hartford, Connecticut • Fort Wayne, Indiana", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Fort Wayne", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04311710" }, { "nct_id": "NCT02756988", "title": "18615 - Sun Protection Factor Assay", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sunscreening Agent" ], "interventions": [ { "name": "Coppertone (BAY987704)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2015-10-19", "completion_date": "2015-10-21", "has_results": false, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 1, "location_summary": "Union, New Jersey", "locations": [ { "city": "Union", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756988" }, { "nct_id": "NCT04235270", "title": "A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "FDC of Macitentan and Tadalafil", "type": "COMBINATION_PRODUCT" }, { "name": "Macitentan", "type": "DRUG" }, { "name": "Tadalafil", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 62, "start_date": "2020-01-17", "completion_date": "2020-07-17", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04235270" }, { "nct_id": "NCT04259346", "title": "A Study of Two Formulations of Ixekizumab in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 245, "start_date": "2020-02-05", "completion_date": "2021-02-19", "has_results": true, "last_update_posted_date": "2022-04-08", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 4, "location_summary": "Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Dallas", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04259346" }, { "nct_id": "NCT05236231", "title": "A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Macitentan 10 mg", "type": "DRUG" }, { "name": "Tadalafil 20 mg", "type": "DRUG" }, { "name": "Macitentan 10 mg/Tadalafil 20mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actelion", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2022-02-04", "completion_date": "2022-05-14", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05236231" }, { "nct_id": "NCT01281475", "title": "A Trial of Levodopa in Angelman Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Angelman Syndrome" ], "interventions": [ { "name": "Levodopa", "type": "DRUG" }, { "name": "Placebo Oral Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wen-Hann Tan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "4 Years to 12 Years" }, "enrollment_count": 67, "start_date": "2011-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Greenwood", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281475" }, { "nct_id": "NCT04762680", "title": "Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4", "type": "BIOLOGICAL" }, { "name": "SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3159, "start_date": "2021-02-24", "completion_date": "2023-06-29", "has_results": true, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04762680" }, { "nct_id": "NCT03980522", "title": "A Pilot Study of KPL-914 in Recurrent Pericarditis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Pericarditis" ], "interventions": [ { "name": "KPL-914", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kiniksa Pharmaceuticals (UK), Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "6 Years to 75 Years" }, "enrollment_count": 26, "start_date": "2018-01-24", "completion_date": "2019-05-17", "has_results": true, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-11-06T15:17:48.430Z", "location_count": 14, "location_summary": "Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Oak Brook", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03980522" } ] }